. 2020 May 19;20:176. doi: 10.1186/s12935-020-01262-3

Table 2.

Performance of previously published protein prognostic biomarker candidates in OSskcm

Gene symbol	Literature data				Validation results
Gene symbol	References	n	Survival endpoint	Prognostic significance of high expression	HR (95%CI)	Log-rank P value	Datasets	Cut off
KLK7	[20]	45	OS	Good	2.65 (1.27–5.53)^†	0.0095	GSE17275	Upper 25%
					3.60 (1.48–8.80)^†	0.0049	GSE19234	Upper 25%
					1.93 (1.40–2.65)^†	< 0.0001	TCGA	Upper 25%
MITF	[29]	200	OS	Poor	1.43 (1.09–1.87)^†	0.0104	TCGA	Upper 50%
					3.46 (1.42–8.42)^†	0.0063	GSE19234	Upper 50%
					3.33 (1.18–9.41)^†	0.0230	GSE98394	Upper 50%
KIF20A	[30]	61	RFS	Poor	2.17 (1.12–4.20)^†	0.0218	GSE22155	Upper 25%
					2.56 (1.20–5.47)^†	0.0151	GSE50509	Upper 25%
					3.21 (1.26–8.20)^†	0.0147	GSE98394	Upper 25%
					2.44 (1.02–5.83)^†	0.0454	GSE19234	Upper 25%
CTHRC1	[31]	35	OS	Poor	3.41 (1.31–8.89)^†	0.0122	GSE98394	Upper 25%
TFAP2A	[32]	Nearly 600	DSS	Poor	1.59 (1.03–2.47)^‡	0.0379	GSE65904	Upper 25%
ATF2	[33]	544	OS	Poor	3.05 (1.56–5.97)^†	0.0012	GSE22155	Upper 25%
NCOA3	[34]	343	RFS and DSS	Poor	1.79 (1.17–2.74)^‡	0.0071	GSE65904	Upper 25%
BCL2	[35]	339	OS	Good	0.21 (0.04–0.97)^†	0.0458	GSE22155	Upper 25%
BIRC5	[36]	50	DFS and OS	Poor	3.73 (1.44–9.67)^†	0.0068	GSE98394	Upper 25%
MCAM	[37]	76	OS	Poor	4.66 (1.78–12.18)^†	0.0017	GSE19234	Upper 25%
PLAT	[38]	214	DMFI and OS	Poor	2.24 (1.16–4.34)^†	0.0164	GSE22155	Upper 25%
					3.88 (1.47–10.24)^†	0.0063	GSE98394	Upper 25%
NOS2	[39]	132	DSS and OS	Poor	1.41 (1.07–1.85)^†	0.0131	TCGA	Upper 50%
CDKN1B	[40]	383	DSS and OS	Poor	0.48 (0.24–0.95)^†	0.0341	GSE22155	Upper 25%
					0.69 (0.50–0.95)^†	0.0235	TCGA	Upper 25%
BCL6	[41]	88	6-year OS	Poor	0.57 (0.40–0.80)^†	0.0011	TCGA	Upper 25%
FXYD5	[42]	115	OS	Poor	3.10 (1.24–7.76)^†	0.0159	GSE19234	Upper 25%
DDIT3	[43]	106	OS	Good	5.74 (2.18–15.13)^†	0.0004	GSE98394	Upper 25%
MCAT	[44]	1270	DFI and OS	Poor	5.75 (1.26–26.10)^†	0.0236	GSE22155	Upper 25%
					4.51 (1.72–11.82)^†	0.0021	GSE98394	Upper 25%
CTNNB1	[45]	202	DSS	Good	1.55 (1.02–2.37)^‡	0.0412	GSE65904	Upper 25%
					1.75 (1.15–2.67)^‡	0.0088	GSE65904	Upper 25%
AKT1	[46]	222	5-year DSS or OS	Poor	6.41 (2.39–17.23)^†	0.0002	GSE98394	Upper 25%
					1.53 (1.13–2.06)^†	0.0056	TCGA	Upper 25%
RUNX3	[47]	421	5-year OS	Good	3.75 (1.36–10.33)^†	0.0107	GSE50509	Upper 25%
			5-year DSS		1.81 (1.18–2.76)^‡	0.0062	GSE65904	Upper 25%
BBC3	[48]	158	5-year DSS or OS	Poor	3.62 (1.38–9.52)^†	0.0092	GSE98394	Upper 25%
MMP2	[49]	157	DSS and RFS	Poor	1.41 (1.06–1.89)^‡	0.0197	TCGA	Upper 50%
SPP1	[50]	345	RFS	Poor	9.42 (3.46–25.67)^†	< 0.0001	GSE98394	Upper 25%
TNC	[51]	98	DFS	Poor	1.54 (1.01–2.34)^‡	0.0434	GSE65904	Upper 25%
CCNA2	[52]	245	RFS	Poor	2.23 (1.02–4.88)^†	0.0437	GSE50509	Upper 25%
RGS1	[53]	40	DSS	Poor	2.74 (1.03–7.24)^†	0.0425	GSE98394	Upper 25%
					3.24 (1.31–8.00)^†	0.0110	GSE19234	Upper 25%
					2.66 (1.07–6.65)^†	0.0357	GSE19234	Upper 25%
SPARC	[54]	112	DFS	Poor	2.78 (1.21–6.34)^†	0.0154	GSE50509	Upper 25%
CXCR4	[55]	71	DFS and OS	Poor	0.70 (0.51–0.97)^†	0.0315	TCGA	Upper 25%
RBM3	[56]	246	OS	Good	NS	NS	–	–
EPAS1	[57]	46	DSS	Poor	3.51 (1.56–7.91)^†	0.0024	GSE50509	Upper 25%

NS not significance, RFS recurrence-free survival, DFS disease-specific survival, DFI disease-free interval, DMFI distant metastasis-free interval

^†,‡HR (95%CI) and Log-rank P value of overall survival (OS) and disease-specific survival (DSS)